The Filing Desk

Moderna vs Pfizer

Moderna MRNA · Pfizer PFE · Health Care

Pfizer reported revenue of $62.6 billion in fiscal 2025, 32.2 times Moderna's $1.9 billion in fiscal 2025. Moderna's revenue fell 39.9% in its latest year, and Pfizer's fell 1.6%. Free cash flow was −$2.1 billion at Moderna and $9.1 billion at Pfizer.

Side by side

ModernaPfizer
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1.9B$62.6B
Revenue growth−39.9%−1.6%
Revenue growth a year, last 5 years19.3%8.5%
Gross margin55.4%74.3%
Operating margin−158.1%—
Net margin−145.2%12.4%
Free cash flow−$2.1B$9.1B
Free cash flow margin−106.2%14.5%
Return on capital−65.4%7.2%
Net debt to EBITDA—3.2x
Dividends and buybacks$2M$9.8B
Change in diluted share count1.3%0.2%
Last close$199.33$27.54
P/E at the last close—39.3×
Insider trades, last 12 monthssold $98.5 millionbought $3.0 million, sold $134,661
Piotroski F-score2 of 96 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ModernaPfizer
Operating margin
Percent of revenue
ModernaPfizer
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ModernaPfizer

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Moderna and Pfizer pages.